In the VERIFY study rusfertide demonstrated both safety and efficacy in reducing phlebotomy dependence for patients with polycythemia …
In the VERIFY study rusfertide demonstrated both safety and efficacy in reducing phlebotomy dependence for patients with polycythemia …
Company Overview and Focus Biodexa Pharmaceuticals PLC, a clinical-stage biotechnology company dedicated to developing innovative treatments for diseases …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
Analysts predict transformative biotherapies to lead future cancer treatment breakthroughs, with Oncolytics poised for key role.
Dual GLP-1 and GIP receptor agonist VK2735 moves into pivotal trials targeting robust weight loss and glycemic control …
Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
CEO Lamballe highlights strategic advances, upcoming trial readouts, and expansion of microbiome ecosystem therapies pipeline.
Phase 3 trial data show promising metabolic improvements and durable weight reduction, expanding potential treatment options for millions.
Sustained-release axitinib hydrogel shows promising efficacy and safety in wet age-related macular degeneration and diabetic retinopathy, setting foundation …
First biologic approved for this rare autoimmune blistering skin disease; pivotal trial data drive swift Priority Review.
Already a subscriber? Log in